522 related articles for article (PubMed ID: 30772512)
21. Differences in maxillomandibular morphology among patients with mucopolysaccharidoses I, II, III, IV and VI: a retrospective MRI study.
Koehne T; Köhn A; Friedrich RE; Kordes U; Schinke T; Muschol N; Kahl-Nieke B
Clin Oral Investig; 2018 Apr; 22(3):1541-1549. PubMed ID: 29046964
[TBL] [Abstract][Full Text] [Related]
22. Urinary glycosaminoglycans as a potential biomarker for evaluating treatment efficacy in subjects with mucopolysaccharidoses.
Kakkis E; Marsden D
Mol Genet Metab; 2020 May; 130(1):7-15. PubMed ID: 32224020
[TBL] [Abstract][Full Text] [Related]
23. Transplant outcomes in mucopolysaccharidoses.
Prasad VK; Kurtzberg J
Semin Hematol; 2010 Jan; 47(1):59-69. PubMed ID: 20109613
[TBL] [Abstract][Full Text] [Related]
24. Open issues in Mucopolysaccharidosis type I-Hurler.
Parini R; Deodato F; Di Rocco M; Lanino E; Locatelli F; Messina C; Rovelli A; Scarpa M
Orphanet J Rare Dis; 2017 Jun; 12(1):112. PubMed ID: 28619065
[TBL] [Abstract][Full Text] [Related]
25. Ophthalmological Findings in Mucopolysaccharidoses.
Tomatsu S; Pitz S; Hampel U
J Clin Med; 2019 Sep; 8(9):. PubMed ID: 31540112
[TBL] [Abstract][Full Text] [Related]
26. [Treatment of 2 children with mucopolysaccharidosis by allogeneic hematopoietic stem cell transplantation].
Chen J; Jiang H; Dong L; Wang Y; Luo C; Zhou M; Zhang W; Huang S; Gu X; Qiu W; Zhang H; Gu L
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Dec; 25(6):675-7. PubMed ID: 19065530
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic Options for Mucopolysaccharidoses: Current and Emerging Treatments.
Sawamoto K; Stapleton M; Alméciga-Díaz CJ; Espejo-Mojica AJ; Losada JC; Suarez DA; Tomatsu S
Drugs; 2019 Jul; 79(10):1103-1134. PubMed ID: 31209777
[TBL] [Abstract][Full Text] [Related]
28. An update on ocular involvement in mucopolysaccharidoses.
Ganesh A; Bruwer Z; Al-Thihli K
Curr Opin Ophthalmol; 2013 Sep; 24(5):379-88. PubMed ID: 23872816
[TBL] [Abstract][Full Text] [Related]
29. Clinical outcomes following hematopoietic stem cell transplantation for the treatment of mucopolysaccharidosis VI.
Turbeville S; Nicely H; Rizzo JD; Pedersen TL; Orchard PJ; Horwitz ME; Horwitz EM; Veys P; Bonfim C; Al-Seraihy A
Mol Genet Metab; 2011 Feb; 102(2):111-5. PubMed ID: 20980181
[TBL] [Abstract][Full Text] [Related]
30. Glycosaminoglycan levels in dried blood spots of patients with mucopolysaccharidoses and mucolipidoses.
Kubaski F; Suzuki Y; Orii K; Giugliani R; Church HJ; Mason RW; Dũng VC; Ngoc CT; Yamaguchi S; Kobayashi H; Girisha KM; Fukao T; Orii T; Tomatsu S
Mol Genet Metab; 2017 Mar; 120(3):247-254. PubMed ID: 28065440
[TBL] [Abstract][Full Text] [Related]
31. Hematopoietic Stem Cell Transplantation for Patients with Mucopolysaccharidosis II.
Kubaski F; Yabe H; Suzuki Y; Seto T; Hamazaki T; Mason RW; Xie L; Onsten TGH; Leistner-Segal S; Giugliani R; Dũng VC; Ngoc CTB; Yamaguchi S; Montaño AM; Orii KE; Fukao T; Shintaku H; Orii T; Tomatsu S
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1795-1803. PubMed ID: 28673849
[TBL] [Abstract][Full Text] [Related]
32. The natural history of neurocognition in MPS disorders: A review.
Shapiro EG; Eisengart JB
Mol Genet Metab; 2021 May; 133(1):8-34. PubMed ID: 33741271
[TBL] [Abstract][Full Text] [Related]
33. Changes in Corneal Clouding Over Time in Patients With Mucopolysaccharidosis.
McGrath O; Sornalingam K; Aslam T; Ashworth J
Cornea; 2023 Aug; 42(8):992-999. PubMed ID: 36857777
[TBL] [Abstract][Full Text] [Related]
34. Developmental and behavioral aspects of mucopolysaccharidoses with brain manifestations - Neurological signs and symptoms.
Shapiro EG; Jones SA; Escolar ML
Mol Genet Metab; 2017 Dec; 122S():1-7. PubMed ID: 29074036
[TBL] [Abstract][Full Text] [Related]
35. Ex Vivo and In Vivo Gene Therapy for Mucopolysaccharidoses: State of the Art.
Consiglieri G; Bernardo ME; Brunetti-Pierri N; Aiuti A
Hematol Oncol Clin North Am; 2022 Aug; 36(4):865-878. PubMed ID: 35773049
[TBL] [Abstract][Full Text] [Related]
36. Activities of daily living in patients with Hunter syndrome: impact of enzyme replacement therapy and hematopoietic stem cell transplantation.
Tanjuakio J; Suzuki Y; Patel P; Yasuda E; Kubaski F; Tanaka A; Yabe H; Mason RW; Montaño AM; Orii KE; Orii KO; Fukao T; Orii T; Tomatsu S
Mol Genet Metab; 2015 Feb; 114(2):161-9. PubMed ID: 25468646
[TBL] [Abstract][Full Text] [Related]
37. Treatment of brain disease in the mucopolysaccharidoses.
Scarpa M; Orchard PJ; Schulz A; Dickson PI; Haskins ME; Escolar ML; Giugliani R
Mol Genet Metab; 2017 Dec; 122S():25-34. PubMed ID: 29153844
[TBL] [Abstract][Full Text] [Related]
38. Novel Enzyme Replacement Therapies for Neuropathic Mucopolysaccharidoses.
Sato Y; Okuyama T
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936354
[TBL] [Abstract][Full Text] [Related]
39. [Principles of therapeutic approaches for mucopolysaccharidoses].
Caillaud C
Arch Pediatr; 2014 Jun; 21 Suppl 1():S39-45. PubMed ID: 25063383
[TBL] [Abstract][Full Text] [Related]
40. Long-Term Follow-up Posthematopoietic Stem Cell Transplantation in a Japanese Patient with Type-VII Mucopolysaccharidosis.
Orii K; Suzuki Y; Tomatsu S; Orii T; Fukao T
Diagnostics (Basel); 2020 Feb; 10(2):. PubMed ID: 32079065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
